Template:Psilocin activities
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 49–567 (Ki) 853–>3,160 (EC50) 0.7% (Emax) |
| 5-HT1B | 31–305 |
| 5-HT1D | 19–36 |
| 5-HT1E | 44–52 |
| 5-HT1F | ND |
| 5-HT2A | 6.0–340 (Ki) 2.4–3,836 (EC50) 16–98% (Emax) |
| 5-HT2B | 4.6–410 (Ki) 2.4–>20,000 (EC50) 1.4–84% (Emax) |
| 5-HT2C | 10–141 (Ki) 30.3 (EC50) 95.1% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | 70–84 |
| 5-HT6 | 57–72 |
| 5-HT7 | 3.5–72 |
| α1A–α1B | >10,000 |
| α2A | 1,379–2,044 |
| α2B | 1,271–1,894 |
| α2C | 4,404 |
| β1–β2 | >10,000 |
| D1 | 20–>14,000 |
| D2 | 3,700–>10,000 |
| D3 | 101–8,900 |
| D4 | >10,000 |
| D5 | >10,000 |
| H1 | 1,600–>10,000 |
| H2–H4 | >10,000 |
| M1–M5 | >10,000 |
| σ1 | >10,000 |
| σ2 | >10,000 |
| I2 | 792 |
| TAAR1 | 1,400 (Ki) (rat) 17,000 (Ki) (mouse) 920–2,700 (EC50) (rodent) >30,000 (EC50) (human) |
| SERT | 3,800–>10,000 (Ki) 662–3,900 (IC50) 561 (EC50) 54% (Emax) |
| NET | 13,000 (Ki) 14,000 (IC50) >10,000 (EC50) |
| DAT | 6,000–>30,000 (Ki) >100,000 (IC50) >10,000 (EC50) |
| Notes: The smaller the value, the more avidly psilocin interacts with the site. Sources: [1][2][3][4][5][6][7][8][9][10] | |
Template documentationSee also
References
- ^ Liu T. "BindingDB BDBM50081701 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol::4-hydroxy-N,N-dimethyltryptamine::CHEMBL65547::N,N-dimethyl-4-hydroxytryptamine::Psilocin::US11427604, Compound (I-45)::US11453689, Compound Psilocin::US11591353, Compound I-45::US11597738, Example 3::US11642336, Compound Psilocin::US20240051978, Compound Psilocin". BindingDB. Retrieved 5 September 2024.
- ^ Liu T. "BindingDB BDBM50171269 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate::4-phosphoryloxy-N,N-dimethyltryptamine::CHEMBL194378::Indocybin::O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine::Psilocybine::US11597738, Example 4::psilocin phosphate ester::psilocybin". BindingDB. Retrieved 5 September 2024.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 2024-09-05.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 2024-09-05.
- ^ Holze F, Singh N, Liechti ME, D'Souza DC (May 2024). "Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 472–489. doi:10.1016/j.bpsc.2024.01.007. PMID 38301886.
- ^ Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M (August 2023). "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy" (PDF). CNS Spectr. 28 (4): 416–426. doi:10.1017/S1092852922000888. PMID 35811423.
- ^ Tylš F, Páleníček T, Horáček J (March 2014). "Psilocybin - summary of knowledge and new perspectives". Eur Neuropsychopharmacol. 24 (3): 342–356. doi:10.1016/j.euroneuro.2013.12.006. PMID 24444771.
- ^ Wojtas A, Gołembiowska K (December 2023). "Molecular and Medical Aspects of Psychedelics". Int J Mol Sci. 25 (1): 241. doi:10.3390/ijms25010241. PMC 10778977. PMID 38203411.
- ^ Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). Eur Neuropsychopharmacol. 26 (8): 1327–1337. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487.
- ^ Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2) e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- ^ Plazas E, Faraone N (February 2023). "Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents". Biomedicines. 11 (2): 461. doi:10.3390/biomedicines11020461. PMC 9953455. PMID 36830997.
- ^ US 11440879, Andrew Carry Kruegel, "Methods of treating mood disorders", published 10 February 2022, assigned to Gilgamesh Pharmaceuticals, Inc.
- ^ Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics. 341 (1): 251–262. doi:10.1124/jpet.111.188946. PMC 3364510. PMID 22271821.
- ^ Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
- ^ Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, Raines S, Hughes ZA, Austin EW, Klein AK, Leong W, Krol FJ, Graaf AJ, Juachon MJ, Otto ME, Borghans LG, Jacobs G, Kruegel AC, Sporn J (October 2025). "A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer". J Psychopharmacol 2698811251378512. doi:10.1177/02698811251378512. PMID 41099491.
- ^ Wsół A (December 2023). "Cardiovascular safety of psychedelic medicine: current status and future directions". Pharmacol Rep. 75 (6): 1362–1380. doi:10.1007/s43440-023-00539-4. PMC 10661823. PMID 37874530.
- ^ Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, Press DJ, Raithatha SA, Hagel JM, Facchini PJ (October 2023). "A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines". J Biol Chem. 299 (10) 105231. doi:10.1016/j.jbc.2023.105231. PMC 10570959. PMID 37690691.
- ^ Chen X, Li J, Yu L, Dhananjaya D, Maule F, Cook S, Chang L, Gallant J, Press D, Bains JS, Raithatha S, Hagel J, Facchini P (10 March 2023), Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery (PDF), doi:10.21203/rs.3.rs-2667175/v1, retrieved 18 March 2025
- ^ Gainetdinov RR, Hoener MC, Berry MD (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev. 70 (3): 549–620. doi:10.1124/pr.117.015305. PMID 29941461.